Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSKVX000000030825
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
GSKVX000000030825 is an investigational biological component of a recombinant protein-based immunotherapy developed by GSK for the treatment and prevention of herpes simplex virus (HSV) infections, specifically genital herpes caused by HSV-2. It is currently being evaluated in Phase I/II clinical trials (e.g., trial 2024-510571-37-00) as part of a multi-component vaccine candidate that typically includes recombinant viral glycoproteins and a proprietary adjuvant system such as AS01. The immunotherapy is designed to elicit robust humoral and cellular immune responses to reduce viral shedding and the frequency of clinical recurrences in infected individuals, while also providing potential prophylactic protection in seronegative adults.
02
Targets
gD (HSV-2 glycoprotein D)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on GSKVX000000030825.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSKVX000000030825.